Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK R1275Q |
Therapy | Ceritinib + Ribociclib |
Indication/Tumor Type | neuroblastoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK R1275Q | neuroblastoma | sensitive | Ceritinib + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Zykadia (ceritinib) and Kisqali (ribociclib) synergistically inhibited proliferation and Alk phosphorylation and induced cell cycle arrest in neuroblastoma cell lines harboring ALK R1275Q in culture (PMID: 27986745). | 27986745 |
PubMed Id | Reference Title | Details |
---|---|---|
(27986745) | Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. | Full reference... |